Ardelyx Inc (NAS:ARDX)
$ 4.905 -0.165 (-3.25%) Market Cap: 1.16 Bil Enterprise Value: 1.11 Bil PE Ratio: 0 PB Ratio: 7.32 GF Score: 75/100

Ardelyx Inc XPHOZAH FDA Approval Conference Call Transcript

Oct 18, 2023 / 12:00PM GMT
Release Date Price: $3.91 (+13.33%)
Operator

[Hello and welcome to the Ardelyx Corporate Update Conference Call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to Caitlin Lowie. Please go ahead, ma'am.]

Caitlin Lowie
Ardelyx, Inc. - VP of Corporate Communications & IR

Thank you. Good morning, everyone, and welcome to our call. Yesterday, we issued a press release announcing the FDA approval of XPHOZAH and a second press release announcing an amended loan agreement. During this call, we will refer to the press releases, which are available on the Investors section of the company's website at ardelyx.com.

During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review our risk factors in our most recent quarterly report on Form 10-Q that was filed in August and can be found on our website at ardelyx.com. While we may elect to update these forward-looking statements in the future, we specifically

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot